Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefditoren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | FAP | Q12884 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 3/20 | 0.66 |
| ▸ | APAF1 | O14727 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.66 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.66 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.66 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefditoren SCHEMBL27465514 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL183495 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL13986532 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL37473 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL16072829 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL1650584 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL2925672 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL183494 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL157719 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefditoren SCHEMBL27465513 | 0.94 | MAPT (0.79) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-03-05 | — | — | US | claimed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115505029-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114040778-A | Cell binding molecule-Tubulysin derivative conjugate and preparation method thereof | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-112826940-A | Conjugates of cytotoxic molecules and cell-binding receptor molecules | 杭州多禧生物科技有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-105641707-B | Conjugates of cytotoxic molecules and cell-binding receptor molecules | 杭州多禧生物科技有限公司 | 2020-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | TDP1 1199/4885MAPT 1665/4885ABCC4 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.